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 Despite its declining incidence, gastric cancer remains a worldwide 
health problem that accounts for 10% of all new cancer diagnoses 
and 12% of all cancer-related deaths ( 1 ). Diagnosis of gastric can-
cer is often made when the disease is advanced and unresectable, 
which contributes to the high rate of morbidity and mortality. 
Complete gastric surgical resection with dissection of lymph nodes 
adjacent to the tumor or more extensive dissection (D 1 – D 4 ) is the 
only potentially curative treatment for patients with gastric cancer 
in stages I – III ( 2 ). For the two-thirds of patients diagnosed as hav-
ing stage II or III gastric cancer, the 5-year survival rate is only 
16% ( 3 ). 
 Several randomized clinical trials have investigated whether 
adjuvant and neoadjuvant chemotherapy with or without radio-
therapy can reduce the rate of recurrence and increase the rate 
of survival ( 4 ). Meta-analyses of some of these trials found that 
 
 Affiliations of authors : Oncologia Medica (FDC, SG) and Dipartimento di 
Patologia Umana ed Oncologia (LM), Azienda Ospedaliero Universitaria 
Careggi, Florence, Italy; Oncologia Medica, Potenza (LM, DB); Oncologia 
Medica, Reggio Emilia (GB); Oncologia Medica, Ospedali Riuniti, Bergamo (RL); 
Oncologia Medica, Città di Castello (SB); Oncologia Medica B, Università La 
Sapienza, Roma (EC); Oncologia Medica A, San Raffaele-IRE, Roma (PC); Clinica 
di Oncologia Medica, Ancona (RB); Dipartimento Medicina Sperimentale, 
Università la Sapienza-Umberto I Roma (ST); Istituto di Patologia Generale, 
Università di Firenze (LM); Istituto di Ricerche Farmacologiche Mario Negri 
Milano (AA, IF); Divisione di Oncologia Medica, Perugia (MT) . 
 Correspondence to: Francesco Di Costanzo, MD, Unit of Medical Oncology, 
Azienda Ospedaliero Universitaria Careggi, Viale Pieraccini 17, 50139 Florence, 
Italy (e-mail:  dicostanzofrancesco@tiscali.it ). 
 See “Funding” and “Notes” following “References.” 
 DOI: 10.1093/jnci/djn054 
 © The Author 2008. Published by Oxford University Press. All rights reserved. 
For Permissions, please e-mail: journals.permissions@oxfordjournals.org. 
 ARTICLE 
 Adjuvant Chemotherapy in Completely Resected 
Gastric Cancer: A Randomized Phase III Trial 
Conducted by GOIRC 
 Francesco  Di Costanzo ,  Silvia  Gasperoni ,  Luigi  Manzione ,  Giancarlo  Bisagni ,  Roberto  Labianca , 
 Stefano  Bravi ,  Enrico  Cortesi ,  Paolo  Carlini ,  Raffaella  Bracci ,  Silverio  Tomao ,  Luca  Messerini , 
 Annarosa  Arcangeli ,  Valter  Torri ,  Domenico  Bilancia ,  Irene  Floriani ,  Maurizio  Tonato 
 On behalf of Italian Oncology Group for Cancer Research 
  Background  Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor. 
  Methods  Patients with histologically proven adenocarcinoma of the stomach of stages IB, II, IIIA and B, or IV 
(T4N2M0) and treated with potentially curative surgery were randomly assigned to follow-up alone or to 
intravenous treatment with four cycles (repeated every 21 days) of PELF (cisplatin [40 mg/m 2 , on days 1 and 
5], epirubicin [30 mg/m 2 , days 1 and 5],  L -leucovorin [100 mg/m 2 , days 1 – 4], and 5-fluorouracil [300 mg/m 2 , 
days 1 – 4] in a hospital setting. Frequencies and severity of adverse events were determined. Overall sur-
vival (OS) and disease-free survival (DFS) were compared between the treatment arms using Kaplan – Meier 
analysis and a Cox proportional hazards regression model. All statistical tests were two-sided. 
  Results  From January 1995 through September 2000, 258 patients were randomly assigned to chemotherapy (n = 
130) or surgery alone (n = 128). Patient characteristics were well balanced between the two arms. Among 
those who received chemotherapy, grade 3 or 4 toxic effects including vomiting, mucositis, and diarrhea 
were experienced by 21.1%, 8.4%, and 11.8% of patients, respectively. Leucopenia, anemia, and thrombo-
cytopenia of grade 3 or 4 were experienced by 20.3%, 3.3%, and 4.2% of patients, respectively. After a 
median follow-up of 72.8 months, 128 patients (49.6%) experienced recurrence and 139 (53.9%) deaths 
were observed, one toxicity-related. Relative to treatment with surgery alone, adjuvant chemotherapy did 
not increase disease-free survival (hazard ratio [HR] of recurrence = 0.92 ; 95% confidence interval [CI] = 
0.66 to 1.27) or overall survival (HR of death = 0.90; 95% CI = 0.64 to 1.26). 
  Conclusions  Our results failed to provide proof of an effect of adjuvant chemotherapy with PELF on overall survival or 
disease-free survival. The estimated effect of chemotherapy (10% reduction in the hazard of death or 
relapse) is modest and consistent with the results of meta-analyses of adjuvant chemotherapy without 
platinum agents. 
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postoperative chemotherapy led to statistically signifi cant reduc-
tions in mortality compared with surgery alone in the range of 
15% – 25%, corresponding to an absolute risk reduction of not 
more than 4% ( 5 – 8 ). 
 Various drug combinations that include platinum compounds, 
anthracyclines, 5-fl uorouracil, taxanes, and/or irinotecan have 
demonstrated promising activity in advanced gastric cancer, with 
overall response rates (ORR) in the range of 37% – 56% and a 
median overall survival (OS) of 9 – 11 months ( 9 – 12 ). In a trial in 
which patients with advanced gastric cancer were randomly 
assigned to a combination of cisplatin, epirubicin, 5-fl uorouracil, 
and leucovorin (PELF regimen) or 5-fl uorouracil, adriamycin, and 
mitomicin-C (FAM), the Italian Oncology Group for Cancer 
Research (GOIRC) observed a statistically signifi cant difference in 
the overall response rate with PELF (ORR = 43% vs 15% in those 
receiving FAM), but patients assigned to PELF did not experience 
a statistically signifi cant improvement in survival compared with 
those assigned to FAM (OS = 8.1 vs 5.6 months, respectively,  P = 
0.24) ( 11 ). Furthermore, in a subsequent trial, GOIRC evaluated 
PELF vs 5-fl uorouracil, adriamycin, and methotrexate (FAMTX) 
in advanced gastric cancer patients and found a statistically signifi -
cant difference in overall response rates (38% vs 21%, respectively, 
 P = 0.009) but no improvement in median time to progression 
(5.9 vs 3.5 months, respectively;  P = .34) or median overall survival 
(7.7 vs 6.9 months, respectively;  P = .19) ( 12 ). 
 On the basis of the activity of the PELF treatment in advanced 
gastric cancer, GOIRC designed a clinical trial to evaluate in an 
adjuvant setting the effi cacy of PELF compared with surgery alone 
in terms of overall survival and disease-free survival (DFS). Because 
some molecular markers (eg, p53, c-erbB2, epidermal growth factor 
receptor [EGFR], E-cadherin, thymidilate synthase [TS]) have 
recently been associated with a poor prognosis and more aggres-
sive gastric cancer ( 13 – 17 ), GOIRC also carried out an exploratory 
analysis of the prognostic value of some of them using a univariate 
Cox proportional hazards model. 
 Methods 
 Patient Eligibility and Surgical Procedures 
 The criteria for inclusion in this study were: a histologically proven 
diagnosis of gastric cancer; radical resection of the tumor not more 
than 8 weeks before the date of random assignment with no evi-
dence of residual disease as determined by staging exams; gastric 
cancer of stages IB, II, IIIA – B, or IV (T4N2M0) according to the 
American Joint Committee on Cancer — Cancer Staging 1992 ( 18 ); 
Eastern Cooperative Oncology Group performance status (ECOG-
PS) less than 2; age 75 years or younger; no previous malignancies 
other than superficial skin cancer or in situ cervical carcinoma; no 
previous treatments such as neoadjuvant chemotherapy or radio-
therapy; and no evidence of abnormal hepatic, renal, or cardiac 
function. Written informed consent and approval by the local eth-
ics committee was obtained for all patients in the study before 
random assignment. 
 Surgical procedures were not standardized among participating 
centers. In the protocol, the minimum surgical recommendations 
included total or subtotal gastrectomy with negative resection 
margins with at least D 1 lymphadenectomy dissection. 
 Study Design 
 The study was designed as a multicenter randomized open-label 
phase III trial. After surgery, patients were randomly assigned to 
receive adjuvant chemotherapy or no further treatment. Random 
assignment was centrally managed at the GOIRC data center. 
Computer-generated permuted-block randomization lists were 
stratified by institution, stage (IB or II vs III or IV), and tumor site 
(upper third vs middle or inferior third of stomach). 
 Treatment Plan 
 In the chemotherapy arm, patients received four cycles of cisplatin 
(40 mg/m 2 given intravenously as a 30-minute infusion on days 1 
and 5), epirubicin (30 mg/m 2 by intravenous bolus injection on days 
1 and 5),  l -leucovorin (100 mg/m 2 by intravenous bolus injection 
on days 1 – 4), and 5-fluorouracil (300 mg/m 2 by intravenous bolus 
injection on days 1 – 4). Cycles were repeated at 21-day intervals. As 
antiemetic therapies, ondansetron (8 mg by intravenous injection 
on days 1 and 5) and dexamethasone (8 mg by intravenous injection 
on days 1 and 5) were administered before and after cisplatin and 
epirubicin treatment. 
 Before and 7 – 10 days after each cycle of chemotherapy, clinical 
evaluation and hematology (white and red blood cell count and 
platelet count) and biochemistry (total bilirubin, aspartate amino 
transferase and alanine amino transferase, creatinine or creatinine 
clearance, blood urea nitrogen, calcium, sodium, potassium elec-
trolytes) examinations were performed to evaluate toxicity, which 
was graded according to the World Health Organization scoring 
system. 
 Baseline Assessment and Follow-up 
 Baseline assessment included taking a complete medical history 
and performing a physical examination. Hematologic evaluation 
included white and red blood cell counts and platelet count. 
Biochemical evaluation consisted of measurement of total plasma 
bilirubin concentration; aspartate amino transferase; alanine amino 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 The effectiveness of adjuvant therapy for patients who are surgically 
treated for gastric cancer was not clear. A combination of epirubicin, 
leucovorin, 5-fluorouracil, and cisplatin, the PELF regimen, had shown 
some benefit over other regimens in terms of patient response. 
 Study design 
 Randomized clinical trial comparing PELF chemotherapy and  follow-
up alone in patients with completely resected gastric cancer. 
 Contribution 
 The PELF regimen was not effective at improving patient survival 
in an adjuvant setting. 
 Implications 
 New strategies and further study will be required to improve sur-
vival in patients who are surgically treated for gastric cancer. 
 Limitations 
 This study was not powered to detect very modest differences in 
patient outcomes between the two treatment arms. 
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transferase; creatinine or creatinine clearance; blood urea nitrogen; 
and calcium, sodium, and potassium electrolytes. Tumor markers 
(CEA and CA-19.9) were measured in the blood of patients before 
treatment. Either an abdominal ultrasound or computed tomo-
graphy (CT) scan and a chest x-ray were required after surgery and 
before random assignment. 
 Follow-up consisted of clinical examination and hematologic 
(white and red blood cell count and platelet count) plus bio-
chemical (total bilirubin; aspartate amino transferase; alanine 
amino transferase; creatinine or creatinine clearance; blood urea 
nitrogen; and calcium, sodium, and potassium electrolytes) evalua-
tion and was performed every 4 months for the fi rst 3 years, then 
every 6 months until the fi fth year, and thereafter at the investiga-
tor ’ s discretion. 
 Endoscopy was performed every 6 months after surgery in the 
fi rst 2 years and thereafter if clinically indicated. Disease recur-
rence (locoregional recurrence and/or metastases) was determined 
by clinical, radiologic, and, whenever possible, histologic examina-
tion. Treatment after relapse was not standardized and was left to 
the discretion of the investigators. 
 Clinical Prognostic Factors and Immunohistochemical 
Markers 
 In all 258 randomly assigned patients, we analyzed the association 
of clinical prognostic factors (age; sex; ECOG-PS; stage according 
to the American Joint Committee on Cancer tumor, node, metas-
tasis staging system; tumor site; tumor histotype; tumor grading 
according to WHO classification ( 19 ); lymph node dissection; total 
number of lymph nodes excised; number of pathologic lymph 
nodes; gastric resection) with overall survival and disease-free 
survival. Because the American Joint Committee on Cancer Tumor 
(AJCC)-International Union Against Cancer node stage changed in 
1997, we used the new classification of lymph nodes in the analyses 
of prognostic factors. 
 An ancillary study was designed to evaluate which molecular 
prognostic factors (p53, c-erbB2, Mib1, TS, or Herg1) were associ-
ated with the risk of relapse and death after curative resection. 
These factors were analyzed in tissues obtained from 145 randomly 
assigned patients (75 in PELF arm and 70 in follow-up arm). 
 Staining procedures for p53, TS, Ki-67, and c-erbB2 were 
conducted using an automated immunostainer (Ventana NexES; 
Ventana Medical Systems, Tucson, AZ) on 4- µ m thick sections 
of paraffin-embedded tissue. Sections were deparaffinized in 
xylene and rehydrated in a descending ethanol series. 
Microwave-based heat induced epitope retrieval was per-
formed. Endogenous peroxidase activity was blocked by immer-
sion for 10 minutes in 0.3% hydrogen peroxide in methanol 
solution, followed by a single wash in phosphate-buffered 
saline (PBS; pH 7.4). The immunohistochemical staining was 
developed for the following primary antibodies: anti-p53 (clone 
DO-7 monoclonal prediluted; Ventana), anti-Ki-67 (Mib1 
monoclonal, dilution 1  :  40; Dako Corporation, Carpinteria 
CA), anti-TS (clone TS106 dilution 1  :  50; Zymed, South 
San Francisco, CA), and c-erbB2 (polyclonal, dilution 1  :  500; 
Dako SA, Glostrup, Denmark). Immunohistochemical studies 
were performed on representative paraffin-embedded tissue 
sections from each patient by using the streptavidin-biotin 
 immunoperoxidase complex method. The immunostaining was 
developed using 3,3 ′ -diaminobenzidine as the chromogen. 
 Immunohistochemistry for Herg1 was performed on 7- µ m 
thick sections of paraffi n-embedded tissue mounted on polylysine-
coated slides. After dewaxing and blocking of endogenous peroxi-
dase, sections were treated with proteinase K (Roche, Mannheim, 
Germany; 5  µ g/mL in PBS) and UltraVBlock solution (LabVision, 
Fremont, CA) containing 0.1% Triton X-100 and then incubated 
with the primary antibody (anti-pan Herg1 antibody (Alexis 
Corporation, Lausanne, Switzerland) diluted 1  :  200 in PBS) over-
night at 4°C. Immunostaining was carried out using a commer-
cially available kit (PicTure Plus kit; Zymed). 
 Appropriate positive and negative controls were included on 
each immunohistochemistry run to confi rm antibody specifi city. 
After immunostaining, the entire section was examined with a light 
microscope at the magnifi cation of ×100 by two independent 
examiners. 
 For p53, TS, c-erbB2, and Herg1, immunoreactivity was scored 
as negative (no immunostaining) or positive. A semiquantitative 
system was used, and the percentage of immunostained cells was 
recorded as follows: 1+ (1% – 25%); 2+ (26% – 50%); 3+ (51% –
 100%). The Ki-67 labeling index was determined by randomly 
counting 1000 tumor cells, and the results were expressed as the 
percentage of positive cells. 
 Statistical Methods 
 The treatment (PELF) and control (follow-up alone) arms were 
compared according to overall survival (the primary endpoint) and 
disease-free survival. Survival time was defined as the interval from 
the date of random assignment to the date of death from any cause 
or the date of last follow-up. Disease-free survival was the interval 
from the date of randomization to the date of the first observation 
of a neoplastic event (relapse or second malignancy) or the date of 
death from any cause. If no progression was reported and no death 
occurred, data on disease-free survival were censored from the date 
when the absence of relapse was last confirmed. 
 The planned sample size was calculated using Lachin’s ( 20 ) 
approach assuming a 5-year survival in the control group of 
30% and a relative mortality reduction of 42% (this corre-
sponds to an absolute increase of 20% in overall survival at 
5 years). Under these assumptions, in a sample of 250 patients 
(125 in each arm), there would be 145 events over 8 years 
(including the accrual period of 5 years) and thus a statistical 
power of 90% and a type I error probability of 5% in a two-
sided comparison. 
 Primary statistical analysis was performed according to the 
intention-to-treat principle. Cumulative overall and disease-free 
survival curves were constructed as time-to-event plots by the 
Kaplan – Meier method. Differences between the curves were 
tested for statistical signifi cance using log-rank statistics (unad-
justed analysis). The two study arms were also compared using a 
Cox proportional hazards regression model that allowed for the 
following covariates in the adjusted analysis: tumor stage, lymph 
node stage, number of examined lymph nodes ( ≤ 15 or  > 15), site of 
disease, and age (in decades) ( 21 ). The proportionality assumption 
was tested by the method of Grambsch and Therneau ( 22 ). 
Treatment, the covariates that were statistically signifi cantly 
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 associated with the outcome, and the fi rst-order interaction terms 
between the treatment and the covariates were entered into the 
fi nal Cox model. The interaction terms made it possible to assess 
whether the treatment effect was modifi ed by the considered 
covariates. For age (considered as a continuous variable), if there 
was statistically signifi cant interaction with treatment, a cut point 
of reasonable clinical interest (such as 60 years) was chosen for 
descriptive purposes. Exploratory analysis of the association of 
selected biologic markers (p53, c-erbB2, Mib1, TS, Herg1) with 
overall survival and disease-free survival was also carried out in the 
subgroup of 145 patients for whom molecular data was obtained, 
and clinical (age, sex, ECOG-PS, stage, tumor site, grading, surgi-
cal type, lymphadenectomy type, total number of lymph nodes 
excised, number of pathologic lymph nodes) and biologic markers 
were considered in the univariate model. The variables were cate-
gorized according to criteria reported previously ( 23 – 25 ). Results 
were reported as hazard ratio (HR) estimates together with the 
corresponding 95% confi dence intervals (CIs) and the  P value 
obtained from the Wald test. Relative and absolute frequencies of 
adverse events and their severity were also calculated. For all the 
computations, we used the SAS software ( 26 ). 
 Results 
 From January 1995 through September 2000, 258 patients were 
randomly assigned by 33 Italian centers, 130 to the chemotherapy 
arm and 128 to no further treatment (follow-up arm;  Figure 1 ). 
Seven patients were considered to be ineligible: one had stage IA 
gastric cancer, two had not undergone radical resection of the pri-
mary tumor, three had metastatic disease, and one was not ran-
domly assigned until 56 days after the date of surgery. The yearly 
accrual rate was similar in the two groups, and the two arms were 
also similar in terms of the distribution of follow-up time for survi-
vors: for the chemotherapy arm, the median follow-up was 5.6 years 
(interquartile range [IQR] = 4.9 – 6.8 years), whereas for the control 
arm, it was 5.9 years (IQR = 3.9 – 6.6 years). 
 Patient and Surgical Procedures 
 In each arm, the median age was 59 years ( Table 1 ) and 61% of 
patients were male; 57% and 54% of patients were surgically 
treated with total gastrectomy in the control and treatment arms, 
respectively. Among all patients, 55% underwent D 2 , D 3 , or D 4 
extended nodal dissection. The median number of removed lymph 
nodes per patient was 16 (range = 4 – 77) in the chemotherapy arm 
and 18 (range = 2 – 68) in the follow-up arm. 
 Chemotherapy 
 The median time from surgery to the beginning of chemotherapy 
was 46 days (range = 5 – 92). In the chemotherapy arm, 13 patients 
(9.8%) never started chemotherapy, and in the follow-up arm, two 
patients were erroneously treated with chemotherapy. 
 A total of 119 patients were treated with adjuvant chemother-
apy. In the chemotherapy arm, 75 patients (58%) completed treat-
ment and in 52 patients (40%) there was some modifi cation of 
dose and/or time. Twenty patients (15% of patients properly 
assigned to chemotherapy) did not receive four complete cycles of 
treatment due to toxic effects during treatment, 15 patients (11%) 
stopped treatment for refusal, and seven patients (5%) stopped for 
other causes ( Table 2 ). 
 Toxicity 
 Data on toxicity were available for 118 of the 119 patients who 
received at least one cycle of chemotherapy ( Table 3 ). Grade 3 – 4 
nausea and vomiting were experienced by 25 (21%) of these 
patients, diarrhea by 14 (12%), mucositis by 10 (8%), and alopecia 
by 29 (25%). Grade 3 – 4 leukopenia was experienced by 24 patients 
(20%). Other toxic effects were rare. One patient death (due to 
cardiovascular complications and electrolytic imbalance after grade 
4 vomiting) was observed. 
 Overall and Disease-Free Survival 
 After a median follow-up of 73 months, 139 patients (54%) had 
died. There were 69 (53%) deaths in the chemotherapy arm and 
70 (55%) deaths in the follow-up arm. There were 11 deaths 
not related to disease progression or second neoplasm, eight in 
the chemotherapy arm (one due to toxicity) and three in the 
control arm. 
 One hundred twenty-eight patients (50%) experienced recur-
rence: 66 (52%) in the follow-up arm and 62 (48%) in the chemo-
therapy arm. There was no difference in the pattern of fi rst sign of 
recurrence (locoregional or systemic) between the two arms. In 
both arms, the most common site of recurrence was the liver (27% 
in the follow-up arm and 29% in the chemotherapy arm), followed 
by the peritoneum (25% in the follow-up arm vs 31% in the che-
motherapy arm) and the lymph nodes (16% in the follow-up arm 
and 17% in the chemotherapy arm). 
 Kaplan – Meier estimates of 5-year overall survival rates were 
47.6% in the chemotherapy arm and 48.7% in the follow-up arm, 
and median overall survival was 56.7 months and 57.6 months, 
  
 Figure 1 .  CONSORT fl ow chart of the Italian Oncology Group for Cancer 
Research phase III trial of cisplatin, epirubicin, 5-fl uorouracil, and leu-
covorin (PELF) vs surgery (ie, follow-up) alone. Enrollment and treat-
ment of patients included in the adjuvant randomized phase III trial in 
resected gastric cancer. F-UP = follow-up; CT = chemotherapy. 
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 Table 1 .  Patient and tumor characteristics * 
 Characteristic
Follow-up alone, N = 128 Chemotherapy, N = 130 Total 
 n (%) n (%) n (%) 
 Sex  
  Male/female 78/50 (61/39) 79/51 (61/39) 157/101 (61/39) 
 WHO PS  
  0 116 (90.6) 118 (90.8) 234 (90.7) 
  1 12 (9.4) 11 (8.5) 23 (8.9) 
  2  – 1 (0.8) 1 (0.4) 
 Primary localization †  
  Upper third 11 (8.6) 10 (7.7) 21 (8.1) 
  Middle third 64 (50) 58 (44.61) 122 (47.3) 
  Lower third 52 (40.6) 60 (46.1) 112 (43.4) 
 Grading  
  G1 and G2 23 (18) 30 (23) 53 (20.5) 
  G3 and G4 74 (57.8) 65 (50) 139 (53.8) 
  Not specified 31 (24.2) 35 (26.9) 66 (25.6) 
 Stage ‡  
  T3/T4 60/8 (46.8/6.2) 64/6 (49.2/4.6) 124/14 (48.6/5.4) 
  No/N+ 22/104 (17.1/81.2) 20/109 (15.3/83.8) 42/213 (16.3/82.5) 
  I/II 12/36 (9.4 / 28.1) 19/32 (14.6/24.6) 99 (38.9) 
  III/IV 75/3 (58.6 / 2.3) 71/7 (54.6/5.4) 156 (60.5) 
 Surgery §  
  Total gastrectomy 73 (57) 70 (53.9) 143 (55.4) 
  Subtotal 54 (42.2) 59 (45.4) 113 (43.8) 
 Lymphadenectomy||  
  D1 44 (34.4) 49 (37.7) 93 (36) 
  D2 57 (44.5) 53 (40.8) 110 (42.7) 
  D3 13 (10.1) 15 (11.5) 28 (10.8) 
  D4 2 (1.6) 3 (2.3) 5 (1.9) 
 No. of lymph nodes examined ¶  
  ≤15 59 (46) 62 (47.7) 121 (46.9) 
  >15 63 (49.2) 65 (50) 128 (49.6) 
 No. of pathologic nodes #  
  ≤ 6 91 (71) 83 (63.9) 174 (67.4) 
  7 – 15 25 (19.5) 36 (27.7) 61 (24) 
  >15 11 (8.6) 11 (8.5) 22 (8.9) 
 *  WHO = World Health Organization; PS = performance status. Median age of patients in the both chemotherapy and follow-up arms was 59 years; ranges were 
32 – 73 and 18 – 71, respectively. 
 †  Data were missing for one and two patients in the follow-up alone and chemotherapy arms, respectively. 
 ‡  Staging according to the American Joint Committee on Cancer tumor, node, metastasis staging system. Data was missing for two patients and one patient in the 
follow-up alone and chemotherapy arms, respectively. 
 §  Data missing for one patient in each arm. 
 || Data missing for 12 and 10 patients in the follow-up alone and chemotherapy arms, respectively. 
 ¶  Data missing for six and three patients in the follow-up alone and chemotherapy arms, respectively; median (range) was 16 (4 – 77) and 18 (2 – 68) in the follow-up 
and chemotherapy arms, respectively. 
 #  Data missing for one patient in the follow-up arm; median (range) was 4 (0 – 29) and 4 (0 – 45) in the follow-up and chemotherapy arms, respectively. 
respectively ( Figure 2 ). Five-year disease-free survival rates were 
42.3% in the chemotherapy arm and 41.6% in the follow-up arm, 
and median disease-free survival was 41.2 months and 34.3 months, 
respectively ( Figure 3 ). Chemotherapy did not lead to an increase 
in either disease-free survival (HR of recurrence in the PELF arm 
vs the follow-up arm = 0.92, 95% CI = 0.66 to 1.27) or overall sur-
vival (HR of death in the PELF arm vs the follow-up arm = 0.90, 
95% CI = 0.64 to 1.26) relative to the control arm. 
 Association of Clinical Variables and Molecular Factors 
With Survival 
 To explore the potential prognostic and predictive value of clin -
ical variables, a multivariable Cox proportional hazards regression 
analysis was performed using the data from all randomly assigned 
patients. Analysis of overall and disease-free survival showed that 
increasing age in decades (HR for death = 1.38, 95% CI = 1.12 to 
1.70,  P = .002; HR for recurrence = 1.32, 95% CI = 1.08 to 1.61, 
 P = .008), fewer examined lymph nodes (HR for death = 0.47, 95% 
CI = 0.32 to 0.37,  P < .001; HR for recurrence = 0.48, 95% CI = 
0.34 to 0.68,  P < .001), increasing tumor stage (HR for death = 1.69, 
95% CI = 1.19 to 2.37,  P = .003; HR for recurrence = 1.88, 95% 
CI = 1.34 to 2.64,  P < .001), and more positive lymph nodes (HR for 
death = 2.96, 95% CI = 2.05 to 4.26,  P < .001; HR for recurrence = 
2.80, 95% CI = 1.96 to 3.99;  P < .001) were statistically significantly 
associated with poorer overall survival and disease-free survival 
( Table 4 ). Moreover, a statistically significant ( P = .022) interaction 
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between age (considered as continuous variable) and treatment was 
detected when we split the sample in two subgroups according to 
age for descriptive purposes. Among younger (<60 years) patients, 
the HR for recurrence in the chemotherapy arm vs follow-up was 
0.94 (95% CI = 0.58 to 1.52), and in the older group, it was 0.58 
(95% CI = 0.35 to 0.96) ( Figure 4 ). Similar patterns were observed 
for overall survival: HR for death = 0.93 (95% CI = 0.57 to 1.53) 
and 0.62 (95% CI = 0.37 to 1.01) for younger and older groups, 
respectively ( Table 4 ). 
 In the subgroup of 145 patients (75 in the PELF arm and 70 in 
follow-up arm) for whom data on biologic factors were also avail-
able, there was no statistical evidence of a relationship between 
p-53, c-erbB2, Mib1, TS, or Herg1 expression and prognosis in 
the univariate model. However, a statistically signifi cant asso-
ciation with mortality and disease-free survival was confi rmed for 
N 2 -N 3 – stage lymph node involvement (according to AJCC-1997) 
and the number of examined lymph nodes ( Table 5 ). 
 Discussion 
 This randomized trial did not show any statistically significant ben-
efit in terms of overall survival or disease-free survival in patients 
with radically resected gastric cancer treated with PELF adjuvant 
chemotherapy relative to those treated by follow-up alone. This 
study was powered to detect larger differences in survival than the 
ones observed here based on very promising results obtained in 
previous randomized trials in advanced gastric cancer ( 11 – 12 ). 
Higher than expected survival rates may have decreased the power 
of our study; nevertheless, the results (HR = 0.9) show that the best 
estimate of the absolute risk reduction in terms of overall survival 
at 5 years is less than 3%. 
 These disappointing results are in agreement with those of 
other recently published trials that showed a higher than antici-
pated survival in the control group and no statistical evidence of 
improvement with chemotherapy. For example, Bajetta et al. ( 27 ) 
randomly assigned 274 gastric cancer patients who had been 
treated with surgery and found to have poor prognostic factors (N+ 
or T3/4) to either adjuvant treatment with a combination of etopo-
side, adriamycin, and cisplatin followed by treatment with 5-fl uo-
rouracil and leucovorin according to the Machover schedule or 
follow-up alone. After a median follow-up of 66 months (range = 
2 – 83), the 5-year overall survival was 52% in the treatment arm 
and 48% in the control arm, whereas the 5-year disease-free sur-
vival was 49% and 44%, respectively. De Vita et al. ( 28 ), after 
treating patients in a randomized trial with radically resected 
gastric cancer with the epirubicin, leucovorin, 5-fl uorouracil, and 
etoposide regimen for six cycles, reported a 5-year overall survival 
rate of 48% in the chemotherapy arm and 43.5% in the control 
 Table 2 .  Compliance with treatment * 
 Treatment characteristic No. (%) 
 Completed treatment 75 (58) 
 Stopped for toxicity 20 (15) 
 Stopped treatment for refusal 15 (12) 
 Stopped for other 7 (5.4) 
 Never started 13 (10) 
 No. of cycles  
  0 13 (10) 
  1 15 (12) 
  2 11 (8.5) 
  3 16 (12) 
  4 75 (58) 
 *  The treatment arm consisted of 130 patients. 
 Table 3 .  Toxicity in patients receiving chemotherapy * 
 Type of toxicity Grades 1 + 2, n (%) Grades 3 + 4, n (%) 
 Hematologic
47 (39.8) 24 (20.3) 
 Leukopenia 
 Thrombocytopenia 14 (11.8) 5 (4.2) 
 Anemia 41 (34.7) 4 (3.3) 
 Nonhematologic
65 (55) 25 (21.1) 
 Nausea/vomiting 
 Diarrhea 39 (33) 14 (11.8) 
 Mucositis 43 (36.4) 10 (8.4) 
 Ototoxicity 4 (3.3) 0 (0) 
 Alopecia 34 (28.8) 29 (24.5) 
 Neurotoxicity 7 (5.9) 1 (0.8) 
 *  Data on toxicity were available on 118 of 119 patients who received at least 
one cycle of chemotherapy. 
 
 Figure 2 .  Overall survival in patients treated with cisplatin, epirubicin, 
5-fl uorouracil, and leucovorin (PELF,  dashed line ) or surgery alone 
( solid line ). Overall survival for all patients randomly assigned to che-
motherapy (CT) arm with PELF ( dashed line ) or follow-up (F-UP) arm 
( solid line ) was estimated using the Kaplan – Meier method. Survival 
time was defi ned as the interval from the date of random assignment 
to the date of death from any cause or the date of last follow-up. Overall 
survival curves were constructed as time-to-event plots by the Kaplan –
 Meier method. Differences between the curves were tested for statisti-
cal signifi cance using log-rank statistics. HR = hazard ratio; CI = 
confi dence interval; EST = estimated fraction of patient alive. 
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(surgery alone) arm and a 5-year disease-free survival rate of 44% 
in the chemotherapy arm and 39% in the control arm. In another 
randomized trial ( 29 ), a French group compared treatment with 
5-fl uorouracil administered as a continuous infusion started before 
day 14 after resection and followed by four subsequent cycles of 
5-fl uorouracil plus cisplatin and treatment with surgery alone. 
They reported a 5-year overall survival rate of 46.6% (median 
OS = 44.8 months) in the chemotherapy group vs 41.9% (median 
OS = 42.1 months) in the group treated with surgery alone. The 
5-year disease-free survival rates were 39.8% in the control group vs 
47.6% in the chemotherapy group ( P = .19). Finally, a randomized 
trial by the European Organization for Research and Treatment 
of Cancer–Gastrointestinal and International Collaborative 
Cancer Group ( 30 ) that compared surgery alone vs adjuvant 
FEMTX reported a 5-year overall survival of 44% in the control 
arm and 43% in the treatment arm, with a 5-year disease-free sur-
vival of 42% and 41%, respectively. Long-term survival after ade-
quate surgical treatment has also been reported in other studies. 
 It is well known that the effectiveness of surgery in promoting 
long-term survival depends on the extension of disease and the 
adequacy of surgery (ie, whether all margins are histologically free 
of tumor) ( 31 ). In our trial, a large number of patients (51.4%) had 
15 or more resected nodes (median = 17 [range = 2 – 77] per 
patient). About 55% of the patients received a D 2 or more lymph-
adenectomy. However, there is controversy about the benefi t of 
extended (D 2 or more) lymphadenectomy, as reported in the two 
European trials that compared D 1 vs D 2 lymphadenectomy 
(32,33). There is no doubt that the goal in gastric cancer treatment 
is the complete removal of primary tumor and the affected regional 
lymph nodes. At present, in a considerable part of Europe, surgery 
alone is the standard of care. 
 The higher than expected survival obtained with a good surgery 
in our study may refl ect the fact that a large majority of patients 
underwent a D 1 or D 2 dissection, approaches more frequently used 
in European trials. These more extensive lymphadenectomies may 
have decreased the rate of disease recurrence and lengthened sur-
vival. It is also possible that patients with more complete lymph 
node dissections derive less value from current approaches to adju-
vant therapy, and this may partially explain the modest effi cacy of 
chemotherapy observed in our trial. 
  
 Figure 4 .  Disease-free survival in patients older than 60 years treated with 
cisplatin, epirubicin, 5-fl uorouracil, and leucovorin (PELF,  dashed line ) or 
surgery alone ( solid line ). In this analysis, a statistically signifi cant ( P = 
.022) interaction between age (considered as continuous variable) and 
treatment was detected when we split the sample in two subgroups 
according to age for descriptive purposes. Among younger (<60 years) 
patients, the hazard ratio for disease-free survival in the chemotherapy 
arm vs follow-up arm was 0.94 (95% CI = 0.58 to 1.52), and in the older 
group, it was 0.58 (95% CI = 0.35 to 0.96). HR = hazard ratio; CI = confi -
dence interval; EST = estimated fraction of patient alive; pts = patients.  
 
 Figure 3 .  Disease-free survival in patients treated with cisplatin, epirubi-
cin, 5-fl uorouracil, and leucovorin (PELF;  dashed line ) or surgery alone 
( solid line ). Disease-free survival for all patients randomly assigned to 
chemotherapy (CT) arm with PELF ( dashed line ) or follow-up arm (F-UP; 
 solid line ) was estimated using the Kaplan – Meier method. Disease-free 
survival was the interval from the date of randomization to the date of 
the fi rst observation of a neoplastic event (relapse or second malig-
nancy) or the date of death from any cause. If no progression was 
reported and no death occurred, data on disease-free survival were cen-
sored from the date when the absence or relapse was last confi rmed. 
Disease-free survival curves were constructed as time-to-event plots by 
the Kaplan – Meier method. Differences between the curves were tested 
for statistical signifi cance using log-rank statistics. HR = hazard ratio; 
CI = confi dence interval; EST = estimated fraction of patient alive. 
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 The frailty of gastric cancer patients after surgery combined 
with toxicity of adjuvant chemotherapy could explain the poor 
compliance to chemotherapy and the lack of the treatment effi -
cacy. In our study, only 58% of patients completed the planned 
treatment and 40% of this subgroup modifi ed the dose and 
timing. 
 The potential value of having many different approaches to 
adjuvant treatment of gastric cancer has been underscored in sev-
eral recent trials. For example, in a large US intergroup study, 
treatment with postoperative chemotherapy (5-fl uorouracil plus 
leucovorin) combined with radiotherapy ( 34 ) led to an improve-
ment on overall survival relative to surgery alone (27 months vs 36 
months). This trial was the subject of debate because although a 
D 2 lymph node dissection was recommended, this procedure was 
performed in only 10% of patients and 54% did not undergo 
clearance of regional lymph nodes (N 1 ). 
 Another recent approach to adjuvant treatment of gastric can-
cer was the combination of pre- and postoperative active chemo-
therapy. Utilizing this approach in a randomized study of patients 
with operable gastric or lower esophageal adenocarcinomas, 
Cunningham et al. ( 35 ) reported decreased tumor size and stage 
and a statistically signifi cant improvement in those who were 
treated with cisplatin, epirubicin, and 5-fl uorouracil (ECF) com-
pared with those treated with surgery alone in terms of progression -
free survival (HR = 0.66, 95% CI = 0.53 to 0.81,  P < .001) and 
overall survival (HR = 0.75, 95% CI = 0.60 to 0.93,  P = .009; 
5-year survival rate = 36% vs 23%). However, a recent systematic 
overview of neoadjuvant treatment for gastric cancer that included 
trials of preoperative chemotherapy only did not show any survival 
 benefi t. In the four clinical trials analyzed, among 250 patients 
who received preoperative chemotherapy and 332 patients who did 
not receive preoperative chemotherapy, there were 106 and 126 
 Table 5 .  Univariate analysis of clinical and biologic prognostic factors * 
 Variables Reference category
Overall survival Disease-free survival 
 HR (95% CI)  P value HR (95% CI)  P † value 
 Chemotherapy Follow-up alone 0.70 (0.37 to 1.32) .256 0.73 (0.39 to 1.36) .320 
 Age decades 2.02 (1.26 to 3.24) .003 1.88 (1.17 to 3.00) .008 
 T3 – T4 T1 – T2 1.41 (0.74 to 2.71) .300 1.46 (0.76 to 2.78) .253 
 N2 – N3 ‡ N0 – N1 1.23 (0.64 to 2.37) .541 1.37 (0.72 to 2.63) .336 
 >15 examined nodes  ≤ 15 examined nodes 0.48 (0.25 to 0.92) .028 0.51 (0.27 to 0.98) .043 
 p53 Neg 1.18 (0.70 to 2.06) .575 1.11 (0.63 to 1.93) .721 
 c-erbB2 Neg 0.90 (0.44 to 1.83) .775 0.85 (0.42 to 1.72) .649 
 Mib1 <3 0.88 (0.45 to 1.70) .696 0.76 (0.40 to 1.47) .418 
 TS Neg 1.17 (0.68 to 2.04) .570 1.14 (0.66 to 1.96) .652 
 Herg1 0 – 1 0.84 (0.44 to 1.60) .602 0.76 (0.40 to 1.44) .395 
 *  HR = hazard ratio; CI = confidence interval; T = tumor; N = node; Neg = negative; TS = thymydilate synthase. Exploratory analysis of the association of selected 
biological markers (p53, c-erbB2, Mib-1, TS, and Herg1) with overall survival and disease-free survival was also carried out in the subgroup of 145 patients for 
whom molecular data were obtained and clinical (age, sex, ECOG-PS, stage, tumor site, grading, surgical type, lymphadenectomy type, total number of lymph 
nodes excised, number of pathological lymph nodes) and biological markers were considered in the univariate model. Results were reported as hazard ratio 
estimates, together with the corresponding 95% confidence intervals and the  P value obtained from the Wald test. An HR of 1 denotes the absence of a 
difference between arms (or the two categories of compared covariates), whereas an HR greater than 1 or less than 1 denotes an increased or decreased risk, 
respectively, in a given patient group in comparison with the reference group. 
 †  From the Wald test. 
 ‡  N2 = 7 – 15 involved lymph nodes, N3 = >15 involved lymph nodes. 
 Table 4 .  Effect of patient variables on the risk of death and recurrence as determined by a Cox proportional hazards regression model * 
 Variables Reference category
Overall survival Disease-free survival 
 HR (95% CI)  P value HR (95% CI)  P value † 
 Chemotherapy arm Control arm 0.87 (0.62 to 1.22) .41 0.84 (0.60 to 1.17) .30 
 Age decades 1.38 (1.12 to 1.70) .002 1.32 (1.08 to 1.61) .008 
 Stage  
  T3 – T4 T1 – T2 1.69 (1.19 to 2.37) .003 1.88 (1.34 to 2.64) <.001 
  N2 – N3 ‡ N0 – N1 2.96 (2.05 to 4.26) <.001 2.80 (1.96 to 3.99) <.001 
 >15 examined nodes  ≤ 15 examined nodes 0.47 (0.32 to 0.67) <.001 0.48 (0.34 to 0.68 <.001 
 Interaction chemotherapy / age Treatment effect .056 .022 
  Age  ≤ 60 y 0.93 (0.57 to 1.53) .77 0.94 (0.58 to 1.52) .81 
  Age >60 y 0.62 (0.37 to 1.01) .057 0.58 (0.35 to 0.96) .033 
 *  HR = hazard ratio; CI = confidence interval; T = tumor; N = node. The two study arms were compared using a Cox proportional hazard regression model that 
allowed for the following covariates in the adjusted analysis: tumor stage, lymph node stage, number of examined lymph nodes, and site of disease and age 
(in decades). 
 †  From the Wald test. 
 ‡  N2 = 7 – 15 involved lymph nodes; N3 = >15 involved lymph nodes. 
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deaths at the end of follow-up in the preoperative chemotherapy 
and control group, respectively. For the outcome of death at the 
last follow-up, the odds ratio was 1.05 (95% CI = 0.73 to 1.50). 
The results showed no statistically signifi cant differences 
( P = .29) between the two groups ( 36 ). These data suggest that the 
effect in the Cunningham trial may be due mainly to ECF chemo-
therapy given in the pre- and postoperative phase. 
 Several pathologic factors, including the presence of lymph 
node metastases, site of gastric tumor, depth of tumor invasion, 
and stage, have been considered to be important indicators of 
prognosis. Our exploratory analysis confi rmed the association of 
extent of the primary tumor and the presence of regional lymph 
node metastases. Analysis of interaction between covariates and 
adjuvant treatment suggested that the benefi t of treatment, if any, 
was related to older patients. This result suggesting a possible 
benefi t of treatment in older patients must be interpreted with 
caution because it comes from an exploratory analysis. The ques-
tion of whether age is a real predictive factor for response or a 
marker of other factors needs to be investigated further. 
 Our analysis indicated that additional biomolecular factors 
(p53, c-erbB2, Mib1, TS, and Herg1) previously implicated in 
progression and metastasis of gastric cancer were not associated 
with prognosis in older patients. Even in the relatively small sub-
group of patients with available data, the power of the study was 
suffi cient to rule out medium or large increases in risk associated 
with the presence of these biologic factors. Our results do not 
confi rm fi ndings of other groups ( 37 ) that suggested that immuno-
histochemical examination of biologic markers may be useful in 
predicting the clinical outcomes of gastric cancer patients. 
 Our study had several limitations: in the planning of the study, 
we estimated a 5-year survival of 30% in the control group in 
which we actually observed a 5-year survival of 50%. So, the objec-
tive of a 20% benefi t with adjuvant chemotherapy was optimistic, 
and the sample size was too small to detect a smaller difference. 
Otherwise, the exploratory analysis of clinical prognostic factors 
showed a statistically signifi cant difference in survival in older 
patients (>60 years), con sidering the age as continuous variable, 
treated with adjuvant chemotherapy. The analysis of molecular 
prognostic factors performed did not clarify these results in dis-
ease-free survival and overall survival obtained with chemotherapy 
in older patients. 
 In summary, this randomized study failed to demonstrate a sta-
tistically signifi cant benefi t of PELF as adjuvant chemotherapy in 
terms of overall survival and disease-free survival after curative sur-
gery in patients with gastric cancer. Our study confi rms that a dose-
intense regimen like PELF, which showed very promising results in 
advanced gastric cancer, is not effective in an adjuvant setting. The 
absolute risk reduction that we observed is within the range of 4% 
suggested by the meta-analyses of more than 30 randomized trials 
( 5 – 8 ). The same magnitude of effect was confi rmed by a recent 
study by Cascinu et al. ( 38 ), which found that PELF administered 
in weekly cycles in an adjuvant setting was not superior to 5-fl uoro-
uracil plus leucovorin, thus confi rming that PELF treatment is not 
better than 5-fl uorouracil – based adjuvant chemotherapies. 
 Oral chemotherapy with fl uoropyrimidines (UFT, Capecitabine, 
S-1) is used for adjuvant chemotherapy in gastric cancer in Asian 
countries. Recently, promising results have been reported for S-1 
in the treatment of patients with advanced gastric cancer and in 
patients with radically resected gastric cancer treated with S-1 as 
adjuvant chemotherapy ( 39 ). In a randomized trial of 1059 patients 
with stage II and III gastric cancer who underwent gastrectomy 
plus extended (D 2 ) lymph node dissection, Sakuramoto et al. ( 40 ) 
reported a 3-year overall survival rate of 80.1% (95% CI = 76.0 to 
84.0) in the patients treated with S-1 compared with 70.1% (95% 
CI = 65.5 to 74.6) in the group treated with surgery alone, with an 
HR for death of 0.68 (95% CI = 0.50 to 0.77,  P < .001). The rate 
of relapse-free survival at 3 years was 72.2% (95% CI = 67.9 to 
76.4) in S-1 group and 59.6% (95% CI = 54.9 to 64.3) in the control 
arm with an HR for relapse of 0.62 (95% CI = 0.50 to 0.77,  P = 
.001). These results are promising, but the trial was conducted 
in East Asian patients and all patients received a D 2 dissection of 
lymph nodes. New strategies, such as combining neoadjuvant 
chemotherapy and adjuvant chemotherapy, appear to be promis-
ing ( 35 ), but the role of preoperative chemotherapy alone is still 
not clear. Therefore, for patients with gastric cancer that is 
resectable or has been treated by surigical resection, there are 
two viable options: pre- and postoperative chemotherapy or 
postoperative chemoradiotherapy. Adjuvant chemotherapy alone 
remains a controversial approach in operable gastric cancer, and 
it needs further testing in trials incorporating newer chemo-
therapy combinations including taxanes, irinotecan, and oral 
fl uoropyrimidines. 
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